Nimbolide-based nanomedicine inhibits breast cancer stem-like cells by epigenetic reprogramming of DNMTs-SFRP1-Wnt/β-catenin signaling axis
Open Access
- 9 September 2023
- journal article
- research article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 34, 102031
Abstract
No abstract availableKeywords
Funding Information
- Department of Science and Technology, Ministry of Science and Technology, India
- Life Sciences Institute
- Department of Biotechnology, Ministry of Science and Technology, India
This publication has 64 references indexed in Scilit:
- Redox homeostasis: the linchpin in stem cell self-renewal and differentiationCell Death & Disease, 2013
- EMT and MET in Metastasis: Where Are the Cancer Stem Cells?Cancer Cell, 2012
- Reactive Oxygen Species in Cancer Stem CellsAntioxidants & Redox Signaling, 2012
- PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effectAdvanced Drug Delivery Reviews, 2011
- Association of reactive oxygen species levels and radioresistance in cancer stem cellsNature, 2009
- Frequent epigenetic inactivation of Wnt antagonist genes in breast cancerBritish Journal of Cancer, 2008
- The present and future of nanotechnology in human health careNanomedicine: Nanotechnology, Biology and Medicine, 2007
- Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosisOncogene, 2006
- Enhanced Antiproliferative Activity of Transferrin-Conjugated Paclitaxel-Loaded Nanoparticles Is Mediated via Sustained Intracellular Drug RetentionMolecular Pharmaceutics, 2005
- β‐Catenin (CTNNB1) gene amplification: A new mechanism of protein overexpression in cancerGenes, Chromosomes and Cancer, 2004